| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581710 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 18 Pages |
Abstract
Long-term bosutinib treatment is associated with an apparently reversible decline in renal function with frequency and characteristics similar to renal decline observed with long-term imatinib treatment. Patients with risk factors for Grade ⥠3b eGFR should be monitored closely.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jorge E. Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M. Kantarjian, Jeff H. Lipton, Amit Lahoti, Moshe Talpaz, Ewa Matczak, Elly Barry, Eric Leip, Tim H. Brümmendorf, H. Jean Khoury,